Erratum to: The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): Analysis of sixty-two drugs approved from 2006 to 2010 (Drug Safety (2014) 37, (283-294) DOI: 10.1007/s40264-014-0150-2);The weber effect and the united states food and drug administration's adverse event reporting system (FAERS): Analysis of sixty-two drugs approved from 2006 to 2010

Drug Safety

Volumn 37, Issue 4, 2014, Pages 283-294

  Hoffman, Keith B ^a   Dimbil, Mo ^a   Erdman, Colin B ^a   Tatonetti, Nicholas P ^b   Overstreet, Brian M ^a  

^a AdverseEvents Inc   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMBRISENTAN; ARMODAFINIL; BUDESONIDE PLUS FORMOTEROL; CARVEDILOL; DARUNAVIR; DASATINIB; DICLOFENAC EPOLAMINE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ECULIZUMAB; ETONOGESTREL; FLUTICASONE FUROATE; IXABEPILONE; LAPATINIB; LISDEXAMFETAMINE; METHYLPHENIDATE; NEBIVOLOL; NILOTINIB; PALIPERIDONE; PANITUMUMAB; PRESCRIPTION DRUG; RALTEGRAVIR; RANIBIZUMAB; ROTIGOTINE; SITAGLIPTIN; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VARENICLINE; ZOLEDRONIC ACID;

ARTICLE; DRUG APPROVAL; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, FACTUAL; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84898819018     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0159-6     Document Type: Erratum

References (50)

1. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003;18(1):57-60.
2. FDA. Follow-Up to the November 2009 Early Communication about an Ongoing Safety Review of Sibutramine, Marketed as Meridia. 2010. http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm198206.htm. Accessed Feb 2014.
3. Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ (Clin Res Ed). 2001;323(7309):359.
4. FDA. Safety Information: Vioxx (rofecoxib). 2002. http://www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154520. htm. Accessed Feb 2014.
5. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA, J Am Med Assoc. 2002;287(17):2215-20.
6. Szarfman A, Tonning JM, Doraiswamy PM. Pharmacovigilance in the 21st century: new systematic tools for an old problem. Pharmacotherapy. 2004;24(9):1099-104.
7. Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, et al. Antipsychotics and Torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System Database. Drug Saf Int J Med Toxicol Drug Exp. 2013;36(6):467-79. doi: 10.1007/s40264-013-0032-z.
8. Hochberg AM, Hauben M. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria. Clin Pharmacol Ther. 2009;85(6):600-6. doi: 10.1038/clpt.2009.26.
9. Robertson HT, Allison DB. Drugs associated with more suicidal ideations are also associated with more suicide attempts. PLoS ONE. 2009;4(10):e7312. doi: 10.1371/journal.pone.0007312.
10. Weaver J, Grenade LL, Kwon H, Avigan M. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA). Dermatol Ther. 2009;22(3):204-15. doi: 10.1111/j.1529-8019.2009.01233.x.
11. Bailey S, Singh A, Azadian R, Huber P, Blum M. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles. Drug Saf Int J Med Toxicol Drug Exp. 2010;33(2):139-46. doi: 10.2165/11319000-000000000-00000.
12. Harpaz R, Chase HS, Friedman C. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinform. 2010;11(Suppl 9):S7. doi: 10.1186/1471-2105-11-S9-S7.
13. Moore TJ, Glenmullen J, Furberg CD. Prescription drugs associated with reports of violence towards others. PLoS ONE. 2010;5(12):e15337. doi: 10.1371/journal.pone.0015337.
14. Wang HW, Hochberg AM, Pearson RK, Hauben M. An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf Int J Med Toxicol Drug Exp. 2010;33(12):1117-33. doi: 10.2165/11584390-000000000- 00000.
15. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS ONE. 2011;6(11):e27016. doi: 10.1371/journal.pone.0027016.
16. Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS ONE. 2011;6(12):e28124. doi: 10.1371/journal.pone. 0028124.
17. Takarabe M, Kotera M, Nishimura Y, Goto S, Yamanishi Y. Drug target prediction using adverse event report systems: a pharmacogenomic approach. Bioinformatics. 2012;28(18):i611-8. doi: 10.1093/bioinformatics/bts413.
18. Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci. 2012;9(6):441-6. doi: 10.7150/ijms.4549.
19. Chen HC, Tsong Y, Chen JJ. Data mining for signal detection of adverse event safety data. J Biopharm Stat. 2013;23(1):146-60. doi: 10.1080/10543406. 2013.735780.
20. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539-46. doi: 10.1038/clpt.2013.24.
21. Hoffman KB, Kraus C, Dimbil M, Golomb BA. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS ONE. 2012;7(8):e42866. doi: 10.1371/journal.pone.0042866.
22. FDA U. FDA Adverse Event Reporting System (FAERS) (formerly AERS). 2012. http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/ adversedrugeffects/default.htm. Accessed Feb 2014.
23. Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012;50(6):466-78. doi: 10.1097/MLR.0b013e318245a160.
24. Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf Int J Med Toxicol Drug Exp. 2012;35(5):373-85. doi: 10.2165/11599100-000000000-00000.
25. Busch SH, Frank RG, Leslie DL, Martin A, Rosenheck RA, Martin EG, et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatr Serv. 2010;61(1):11-6. doi: 10.1176/appi.ps.61.1.11.
26. Dasgupta N, Mandl KD, Brownstein JS. Breaking the news or fueling the epidemic? Temporal association between news media report volume and opioid-related mortality. PLoS ONE. 2009;4(11):e7758. doi: 10.1371/journal.pone. 0007758.
27. Conti RM, Dusetzina SB, Herbert AC, Berndt ER, Huskamp HA, Keating NL. The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer. Med Care. 2013;51(7):622-7. doi: 10.1097/MLR.0b013e318290216f.
28. Weber J. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res. 1984;6:1-7.
29. MHRA. Black Triangle Scheme - new medicines and vaccines subject to EU-wide additional monitoring. United Kingdom. 2014. http://www.mhra.gov.uk/ Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/ BlackTriangleproducts/index.htm. Accessed Feb 2014.
30. Davenport MS, Dillman JR, Cohan RH, Hussain HK, Khalatbari S, McHugh JB, et al. Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology. 2013;266(3):773-82. doi: 10.1148/radiol.12120253.
31. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24(6):743-9. doi: 10.1592/phco.24.8.743.36068.
32. Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health. 2008;98(8):1366-71. doi: 10.2105/ajph.2007.124537.
33. Thomsen HS, Webb J. The Lalli and Weber effects and the incidence of acute non-renal adverse reactions to contrast media. Acta Radiol (Stockholm, Sweden: 1987). 2012;53(9):953-4. doi: 10.1258/ar.2012.12a006.
34. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA J Am Med Assoc. 2009;302(7):750-7. doi: 10.1001/jama.2009.1201.
35. Hartnell NR, Wilson JP, Patel NC, Crismon ML. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother. 2003;37(10):1387-91. doi: 10.1345/aph.1C522.
36. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf Int J Med Toxicol Drug Exp. 2001;24(3):233-7.
37. McAdams MA, Governale LA, Swartz L, Hammad TA, Dal Pan GJ. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Pharmacoepidemiol Drug Saf. 2008;17(9):882-9. doi: 10.1002/pds.1633.
38. Chhabra P, Chen X, Weiss SR. Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data. Drug Saf Int J Med Toxicol Drug Exp. 2013;36(11):1117-23. doi: 10.1007/s40264-013-0115-x.
39. Staffa JA, Dal Pan GJ. Regulatory innovation in postmarketing risk assessment and management. Clin Pharmacol Ther. 2012;91(3):555-7. doi: 10.1038/clpt.2011.289.
40. Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med. 2011;171(6):591-3. doi: 10.1001/archinternmed.2011.89.
41. FDA U. Reports Received and Reports Entered into AERS by Year. 2013. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/ AdverseDrugEffects/ucm070434.htm. Accessed Feb 2014.
42. Hoffman KB, Overstreet, BM, Doraiswamy, PM. A Drug Safety ePlatform for Physicians, Pharmacists and Consumers based on Post-Marketing Adverse Events. Drugs and Therapy Studies 2013;3(e4).
43. RxNorm. National Library of Medicine. http://www.nlm.nih.gov/research/ umls/rxnorm/. Accessed Feb 2014.
44. FDA. Pharmacological Class: National Drug File Reference Terminology. 2013. http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ ucm162549.htm. Accessed Feb 2014.
45. FDA. Milestones in Food and Drug Law History. 2005. http://www.fda.gov/ aboutfda/whatwedo/history/milestones/ucm081229.htm. Accessed Feb 2014.
46. FDA. Guidance for Industry: Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products. 2006.
47. Schultz WB. Bolstering the FDA's drug-safety authority. New Engl J Med. 2007;357(22):2217-9. doi: 10.1056/NEJMp078212.
48. Traynor K. Law gives FDA new enforcement clout. Am J Health Syst Pharm Off J Am Soc Health Syst Pharm. 2007;64(22):2314-5. doi: 10.2146/news070094.
49. FDA. Approved Risk Evaluation and Mitigation Strategies (REMS). 2007. http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm111350.htm. Accessed Feb 2014.
50. FDA. FDAAA Title IX: enhanced authorities regarding postmarket safety of drugs. 2008.